Screener
TriSalus Life Sciences, Inc. TLSI Q3 2026 earnings
Reported November 10, 2026 · Before market open
Revenue$12.9MMiss by $1.1M
EPS-$0.15Miss by $0.02
Revenue estimate$14.0M
EPS estimate-$0.13
“The third quarter marked an important period of growth and expansion for TriSalus – we drove double-digit year-over-year growth and received FDA clearance for TriNav Advance, which enables Pressure-Enabled Drug Delivery to small distal vessels through the microcatheter of the physician's choice. This clearance allows us to address the full range of vessels encountered in liver embolization procedures going forward. Looking ahead, we believe we are well positioned for 2027. We more than doubled our commercial footprint over the first half of the year, and although our team productivity has ramped slightly slower than anticipated, our representatives continue to educate and drive further TriNav utilization as they build and strengthen relationships with interventional radiologists. Combined with the launch of TriNav Advance, expanded access to office-based labs through the new G-code, and continued cost discipline, we believe we have laid the foundation for continued growth in 2027 and beyond.”
Next report
Date not yet announcedValuation & ratios
Versus estimates
Revenue
Diluted EPS
FAQ
- When did TriSalus Life Sciences, Inc. report Q3 2026 earnings?
- TriSalus Life Sciences, Inc. (TLSI) reported Q3 2026 earnings on November 10, 2026 before market open.
- What were TriSalus Life Sciences, Inc.'s Q3 2026 revenue and EPS?
- TriSalus Life Sciences, Inc. reported revenue of $12.9M and eps of $-0.15 for Q3 2026.
- Did TriSalus Life Sciences, Inc. beat estimates in Q3 2026?
- Revenue missed the consensus estimate of $14.0M by $1.1M. EPS missed the consensus estimate of $-0.13 by $0.02.
- How did TriSalus Life Sciences, Inc.'s Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 11.3% from $11.6M a year earlier and eps grew 84.4% from $-0.96.
- Where can I find TriSalus Life Sciences, Inc.'s Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-072513) and the 10-Q periodic report (0001628280-26-072515) directly on SEC EDGAR. The filing index links above go to sec.gov.
